AI assistant
Sending…
Corvus Pharmaceuticals, Inc. — Director's Dealing 2025
Jun 6, 2025
32755_dirs_2025-06-06_395c1a69-dc32-4e3b-a9a4-2937d14c3ca3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2025-06-04
Reporting Person: Jones William Benton (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-04 | Common Stock | M | 19357 | $3.5 | Acquired | 173130 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-04 | Warrant (Right to Buy) | $3.5 | M | 19357 | Disposed | 2025-06-30 | Common Stock (19357) | Direct |
Footnotes
F1: Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312 per share.
More from Corvus Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
Mar 26
Major Shareholding Notification
2026
Feb 5
Major Shareholding Notification
2026
Jan 30
Director's Dealing
2026
Jan 30
Major Shareholding Notification
2026
Jan 27
Regulatory Filings
2026
Jan 23
Regulatory Filings
2026
Jan 23
Regulatory Filings
2026
Jan 20